Rezurock
Payments companies reported to CMS as associated with Rezurock. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rezurock, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rezurock
These are the largest totals companies reported as associated with Rezurock. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sagar Patel | Edina, MN | Hematology & Oncology | $175,406.71 |
| Miguel Perales | New York, NY | Medical Oncology | $126,144.27 |
| Paul Shaughnessy | San Antonio, TX | Hematology & Oncology | $112,699.72 |
| Corey Cutler | Boston, MA | Hematology & Oncology | $106,710.63 |
| Amandeep Salhotra | Duarte, CA | Hematology (Internal Medicine) | $88,144.98 |
| Jeremy Pantin | Nashville, TN | Hematology & Oncology | $82,969.93 |
| Philip Pancari | Orlando, FL | Hematology (Internal Medicine) | $67,147.18 |
| Catherine Lee | Seattle, WA | Hematology & Oncology | $57,369.36 |
| Salman Fazal | Pittsburgh, PA | Hematology & Oncology | $53,809.06 |
| Hana Safah | Baton Rouge, LA | Hematology & Oncology | $52,686.66 |
Prescribed Rezurock?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.